Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Presentation TCT Abstracts Posters 2018

Incidence of Clopidogrel Resistance Among South Indian Population Undergoing PCI-A Single Centre Genomic Study of CYP2C19 Polymorphism

Presenter: R. Anantharaman

September 25, 2018

Presentation TCT Abstracts Posters 2018

IMPACT: Improving coronary graft Patency with postoperative Aspirin and Clopidogrel versus Aspirin and Ticagrelor

Presenter: Gerard Devlin

September 25, 2018

Presentation TCT Abstracts Posters 2018

Outcomes of Preoperative Bridging with Intravenous Antiplatelet Therapy in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention

Presenter: Bassel Bou Dargham

September 25, 2018

Presentation TCT Abstracts Posters 2018

Heparin surfaces: Impact of immobilization chemistry for blood contact performance

Presenter: Jennie Forsberg

September 25, 2018

Presentation TCT 2018

GLOBAL LEADERS: A Randomized Trial of Ticagrelor Monotherapy After PCI - Patient-Oriented Clinical Outcomes and Net Adverse Cardiovascular Events

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Patrick W. Serruys

September 24, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Presentation TCT 2018

Clinical Trials for Short DAPT: FDA Perspective

Presenter: Christopher J Popma

September 22, 2018

Presentation TCT 2018

TCT-112: Patient-Oriented Clinical Outcomes and Net Adverse Cardiovascular Event in the Global Leaders Trial

Presenter: George D. Dangas, Germano Di Sciascio, Patrick W. Serruys

September 21, 2018

Presentation ESC 2018

ASCEND Randomized placebo-controlled trial of aspirin

Presenter: Jane Armitage

August 27, 2018

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

Presentation The Structural Heart Disease Summit 2018

Updated Amulet Outcomes and Ongoing Studies in Anticoagulant Indicated and Contraindicated Patients

Presenter: William A. Gray, Gregg W. Stone, DJ Lakkireddy

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Presenter: George D. Dangas

June 21, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Advertisement

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Incidence of Clopidogrel Resistance Among South Indian Population Undergoing PCI-A Single Centre Genomic Study of CYP2C19 Polymorphism

IMPACT: Improving coronary graft Patency with postoperative Aspirin and Clopidogrel versus Aspirin and Ticagrelor

Outcomes of Preoperative Bridging with Intravenous Antiplatelet Therapy in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention

Heparin surfaces: Impact of immobilization chemistry for blood contact performance

GLOBAL LEADERS: A Randomized Trial of Ticagrelor Monotherapy After PCI - Patient-Oriented Clinical Outcomes and Net Adverse Cardiovascular Events

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Clinical Trials for Short DAPT: FDA Perspective

TCT-112: Patient-Oriented Clinical Outcomes and Net Adverse Cardiovascular Event in the Global Leaders Trial

ASCEND Randomized placebo-controlled trial of aspirin

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Updated Amulet Outcomes and Ongoing Studies in Anticoagulant Indicated and Contraindicated Patients

Pharmacotherapy Considerations Trials and Practical Clinical Recommendations

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content